Authors

• Ljiljana Banfić — Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zagreb, Hrvatska — ORCID: 0000-0002-4538-8980

Abstract

Deep venous thrombosis (DVT) in high-risk fragile and cancer patient is associated with increased morbidity and mortality. Fragile patient and cancer associated thrombosis patients are estimated to be large number of more than 50% in DVT population treated for deep vein thrombosis. Increased incidence of major bleeding during the course of anticoagulant therapy very often create dilemmas between the safe treatment regime, appropriate pharmacotherapy and adequate drug dosage. The DVT guidelines are the state of knowledge in diagnosis and treatment and gave us the frame and rules for safe DVT treatment. (1-3) The author will give an overview of DVT treatment standard in high- risk patient and present recent literature data that could increase the awareness and possibilities of new treatment modality. Personalized approach for DVT is mandatory but the results of randomized trials that suggested fewer bleeding events in high-risk patients receiving new anticoagulant drugs might open new and safer era in DVT treatment.

Keywords

venous thrombosis, treatment

DOI

Literature

1. Becattini C, Agnelli G. Treatment of venous thromboembolism with new anticoagulant agents. J Am Coll Cardiol. 2016 Apr 26;67(16):1941–55. https://doi.org/10.1016/j.jacc.2016.01.072
2. Moustafa F, Giorgi Pierfranceschi M, Di Micco P, Bucherini E, Lorenzo A, Villalobos A, et al. RIETE Investigators. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism. Res Pract Thromb Haemost. 2017 Sep 4;1(2):172–9. https://doi.org/10.1002/rth2.12036
3. Banfić L. Guidelines on diagnosis, treatment and prevention of venous thrombosis. Cardiol Croat. 2016;11(9):351–74. https://doi.org/10.15836/ccar2016.351